I have no idea how high the share price will go. However, I have done some fairly simple NPV analysis based on Mercer's statement at the Spotlight Conference. Feel free to pick apart. My view is that any regulatory risk disappears and the risk that remains becomes execution risk...can our sales force hit the targets that have been put out there.
Given that there is US sales potential not included in this analysis, as well as other commercial applications for the product, there should be upside to the valuation.
Assumptions: Sales Margin 75%. Head office costs go up at $7m per year and then increase with sales growth from 2020. Sales growth beyond 2020 is what it was from 2020 over 2019. Anyway, here is what I get:
Column 1
Column 2
Column 3
Column 4
Column 5
Column 6
Column 7
Column 8
0
Revenue $m
Growth %
Net Revenue $M
Head Office Costs $m
EBIT $m
NPV $m
Discount Rate
10%
1
2014
2.6
1.95
7.00
-5.05
-5.05
Exchange Rate
0.91
2
2015
33.6
1192%
25.2
14.00
11.2
10.18182
3
2016
96
186%
72
21.00
51
42.14876
4
2017
267
178%
200.25
28.00
172.25
129.414
5
2018
385
44%
288.75
35.00
253.75
173.3147
6
2019
450
17%
337.5
42.00
295.5
183.4823
7
2020
521
16%
390.75
49.00
341.75
192.909
8
2021
603.2022
16%
452.4016667
56.73
395.670556
203.0416
9
2022
698.3741
16%
523.7805963
65.68
458.098577
213.7064
10
2023
808.562
16%
606.4215348
76.05
530.376352
224.9313
11
2024
936.1352
16%
702.101377
88.04
614.057954
236.7459
12
NPV USD
1604.826
13
NPV AUD
1763.545
TIS Price at posting:
44.0¢ Sentiment: Buy Disclosure: Held